Eli Lilly and contract manufacturer Resilience will invest $750 million to expand U.S. pharmaceutical manufacturing capacity and bolster the domestic medicine supply chain. The investment will create 400 new jobs in Ohio and increase production of critical medicines, including Lilly's KwikPen device.
The investment by Eli Lilly and Resilience aims to bolster the U.S. pharmaceutical supply chain and create jobs, responding to global drugmakers' efforts to increase domestic production amid potential trade policy changes.
Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million to expand pharmaceutical manufacturing capacity in the U.S. and strengthen the domestic medicine supply chain, Resilience announced. The investment is part of a broader trend of global drugmakers increasing U.S. production and stockpiling inventory amid potential tariffs from the Trump administration.
Resilience stated the investment will boost the production of critical medicines and generate 400 new high-skilled jobs in the Cincinnati, Ohio region. The company's manufacturing operations will now include Lilly's KwikPen injectable device, used for treating diabetes and obesity. This multi-year manufacturing partnership between Lilly and Resilience, which commenced in 2023, has already supplied over 150 million doses of medicines in vial and pre-filled syringe formats to U.S. patients.
Edgardo Hernandez, Lilly's head of manufacturing, indicated that the collaboration reflects the drugmaker's commitment to meeting increased demand for its medications. Lilly has committed more than $55 billion to U.S. capital expansion projects since 2020 and plans to begin construction on several recently announced U.S. manufacturing sites this year.